Sustained-release Ganciclovir Implant As Prophylaxis for Cytomegalovirus Retinitis in a Child Undergoing Bone Marrow Transplantation
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Sustained-release drug delivery systems for the treatment of glaucoma.
Kesav N, Capitena Young C, Ertel M, Seibold L, Kahook M Int J Ophthalmol. 2021; 14(1):148-159.
PMID: 33469497 PMC: 7790669. DOI: 10.18240/ijo.2021.01.21.
Stewart S, Dominguez-Robles J, Donnelly R, Larraneta E Polymers (Basel). 2019; 10(12).
PMID: 30961303 PMC: 6401754. DOI: 10.3390/polym10121379.
References
1.
Ghosh F, Bynke G, Bekassy A
. Intravitreal sustained-release ganciclovir implants for severe bilateral cytomegalovirus retinitis after stem cell transplantation. Acta Ophthalmol Scand. 2002; 80(1):101-4.
DOI: 10.1034/j.1600-0420.2002.800121.x.
View
2.
Oktavec K, Nolan K, Brown D, Dunn J, Livingston A, Thorne J
. Clinical outcomes in patients with cytomegalovirus retinitis treated with ganciclovir implant. Am J Ophthalmol. 2012; 153(4):728-33, 733.e1-2.
DOI: 10.1016/j.ajo.2011.09.010.
View
3.
Jeon S, Lee W, Lee Y, Lee D, Lee J
. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. Ophthalmology. 2012; 119(9):1892-8.
DOI: 10.1016/j.ophtha.2012.03.032.
View
4.
McAuliffe P, Hall M, Castro-Malaspina H, Heinemann M
. Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosuppression after bone marrow transplantation. Am J Ophthalmol. 1997; 123(5):702-3.
DOI: 10.1016/s0002-9394(14)71090-6.
View